Skip to main contentAI and Advanced
/
NGLFINE · NSEMarket ticker unavailable · configure an authorised index feed
NG
NSE · Equity shares · Biotechnology & Drugs110.00 · 4.28%
NGL Fine Chem Ltd NGLFINE
NSE:INR 2,680
BSE:INR 3,151
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for NGLFINE
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,570
Day rangeINR 2,505.1 — INR 2,738.9
52-week rangeINR 1,271 — INR 3,570
Volume11,722
Market cap1,934.2
P/E26.45
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)500.95
Net Income (INR Cr)48.13
Rev Growth (5 Year %)14.19
EPS Growth (5 Year %)-3.23
P/E Ratio26.45
Book Value532.2
EPS77.9
Price/BV5.04Computed
Research path: Interpret NGL Fine Chem Ltd's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
NGLFINENGL Fine Chem Ltd1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 545.5 | 433.39 | 355.54 |
| Cash Equivalents | 2.3 | Not available | Not available |
| Other Liabilities Total | 8.28 | 4.17 | 3.38 |
| Long Term Debt | 56.4 | 25.05 | 0 |
| Common Stock Total | 3.09 | 3.09 | 3.09 |
| Other Current Assets Total | 29.21 | 5.31 | 4.35 |
| Total Assets | 545.5 | 433.39 | 355.54 |
| Current Portof LT Debt/Capital Leases | 0.08 | 3.94 | 1.56 |
| Cash | 2.81 | 0.58 | 0.4 |
| Total Equity | 329.23 | 282.43 | 262.63 |
| Long Term Investments | 9.33 | 1 | 4.62 |
| Retained Earnings(Accumulated Deficit) | 326.14 | 279.23 | 259.43 |
| Total Common Shares Outstanding | 0.62 | 0.62 | 0.62 |
| Tangible Book Valueper Share Common Eq | 532.2 | 456.27 | 424.67 |
| Goodwill Net | 0.15 | 0.15 | 0.15 |
| Total Liabilities | 216.27 | 150.96 | 92.9 |
| Total Debt | 108.51 | 77.1 | 34 |
| Short Term Investments | 40.91 | 64.94 | 54.92 |
| Cashand Short Term Investments | 46.02 | 65.53 | 55.31 |
| Total Receivables Net | 130.88 | 109.02 | 106.83 |
| Notes Payable/Short Term Debt | 52.02 | 47.82 | 31.7 |
| Deferred Income Tax | 1.57 | 2.48 | 2.19 |
| Accounts Receivable-Trade Net | 130.88 | 82.37 | 90.18 |
| Property/Plant/Equipment Total-Net | 258.45 | 191.85 | 130.82 |
| Total Current Liabilities | 150.01 | 118.97 | 86.59 |
| Total Inventory | 70.28 | 52.84 | 44.36 |
| Accounts Payable | 64.61 | 57.52 | 49.39 |
| Other Currentliabilities Total | 33.3 | 9.69 | 3.94 |
| Total Long Term Debt | 56.4 | 25.34 | 0.74 |
| Intangibles Net | 0.28 | 0.4 | 0.12 |
| Other Long Term Assets Total | 0.06 | 0.12 | 4.2 |
| Note Receivable-Long Term | 0.84 | 4.49 | 2.96 |
| Total Current Assets | 276.39 | 235.38 | 212.67 |
| Accumulated Depreciation Total | Not available | -73.3 | -61.62 |
| Prepaid Expenses | Not available | 2.68 | 1.82 |
| Additional Paid-In Capital | Not available | 0.12 | 0.12 |
| Property/Plant/Equipment Total-Gross | Not available | 215.42 | 146.92 |
| Capital Lease Obligations | Not available | 0.28 | 0.74 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.26
Price to Sale Ratio3.86
Growth
Debt 5Yr CAGR %45.84
Margins
Operating Margin 12m10.43
Operating Margin 5y Avg10.9
Net Profit Margin 12m9.59
Net Profit Margin 5y10.03
Yield
Dividend Yield %0.05
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskExtreme risk
Board Risk66.4
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,936.6 | 4.65 L | 38.87 | — |
| Divi's Laboratories | INR 7,376.6 | 1.96 L | 74.03 | — |
| Torrent Pharmaceuticals | INR 4,975 | 1.68 L | 76.43 | — |
| Zydus Lifesciences | INR 1,117.65 | 1.11 L | 21.29 | — |
| Cipla | INR 1,409.1 | 1.14 L | 28.01 | — |
Shareholding
Ownership
- Promoter
- 72.49%
- FII
- 0.05%
- Other
- 27.46%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Broad-Based Technical Strength Lifts NGL Fine Chem Ltd to 52-Week High of Rs 3315.5 - MarketsMojoMarket news · 7 Jul 2026, 12:09 pm
Broad-Based Technical Strength Lifts NGL Fine Chem Ltd to 52-Week High of Rs 3315.5 MarketsMojo
Enterprise value to revenue forward of NGL Fine-Chem Ltd. – NSE:NGLFINE - TradingViewMarket news · 6 Jul 2026, 6:16 pm
Enterprise value to revenue forward of NGL Fine-Chem Ltd. – NSE:NGLFINE TradingView
Tangible book value per share of NGL Fine-Chem Ltd. – NSE:NGLFINE - TradingViewMarket news · 4 Jul 2026, 10:43 pm
Tangible book value per share of NGL Fine-Chem Ltd. – NSE:NGLFINE TradingView
NGL Fine Chem Ltd Upgraded to Buy on Strong Technicals and Financial Performance - MarketsMojoMarket news · 16 Jun 2026, 9:00 am
NGL Fine Chem Ltd Upgraded to Buy on Strong Technicals and Financial Performance MarketsMojo
NGL Fine Chem Ltd Sees Strong Price Momentum Shift Amid Bullish Technical Indicators - MarketsMojoMarket news · 15 Jun 2026, 8:21 am
NGL Fine Chem Ltd Sees Strong Price Momentum Shift Amid Bullish Technical Indicators MarketsMojo
NGL Fine Chem Ltd Valuation Shifts Amidst Robust Price Gains - MarketsMojoMarket news · 15 Jun 2026, 8:01 am
NGL Fine Chem Ltd Valuation Shifts Amidst Robust Price Gains MarketsMojo
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.1.7500 per share(35%)Final Dividend
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.7500 per share(35%)Final Dividend
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for NGL Fine Chem Ltd
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- NGLFINE
- BSE Code
- 524774
Questions
Stock FAQ
What is the symbol and ISIN of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has the symbol NGLFINE and ISIN - INE887E01022.
What is the current price of NGL Fine Chem Ltd?
NGL Fine Chem Ltd is currently trading at INR 2,680.00.
What are the year high and year low of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has a year high of INR 3,570.00 and a year low of INR 1,271.00.
What is the market capitalization of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has a market capitalization of INR 1,934.20 crore.
What is the P/E ratio of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has a P/E ratio of 26.45.
What is the dividend yield of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has a dividend yield of 0.05%.
How is the financial performance of NGL Fine Chem Ltd based on revenue, net income, and EPS?
NGL Fine Chem Ltd has revenue of INR 500.95 crore, net income of INR 48.13 crore, and EPS of INR 77.77.
What is the book value of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has a book value of INR 532.20.
What is the debt-to-equity ratio of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of NGL Fine Chem Ltd?
NGL Fine Chem Ltd has a price-to-book ratio of 5.04 and a price-to-sales ratio of 3.86.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.